Plain-English translation of NCT07050940 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether combining anti-PD-1 immunotherapy (a standard treatment for advanced melanoma) with a postbiotic supplement — a type of beneficial compound derived from bacteria — can help the immune system fight cancer more effectively. About half of the participants will receive the immunotherapy alone, and half will receive the immunotherapy plus the postbiotic. The study will compare how well these two approaches work.
Standard immunotherapy has helped many melanoma patients, but it does not work for everyone. Researchers believe that adding a postbiotic might boost the body's immune response and help more patients benefit from this treatment.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to receive either the standard immunotherapy alone or the immunotherapy plus the postbiotic supplement. You will visit the clinic regularly for treatment and monitoring, including blood tests and imaging scans to measure how your cancer responds. The study team will carefully track your health and any side effects throughout your participation.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Italy